1. Home
  2. CHRD vs TGTX Comparison

CHRD vs TGTX Comparison

Compare CHRD & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chord Energy Corporation

CHRD

Chord Energy Corporation

HOLD

Current Price

$112.93

Market Cap

8.2B

Sector

Energy

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$52.39

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHRD
TGTX
Founded
2007
1993
Country
United States
United States
Employees
676
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
8.5B
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
CHRD
TGTX
Price
$112.93
$52.39
Analyst Decision
Buy
Strong Buy
Analyst Count
13
5
Target Price
$149.17
$49.80
AVG Volume (30 Days)
804.9K
2.8M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
3.56%
N/A
EPS Growth
N/A
1746.67
EPS
N/A
0.12
Revenue
N/A
$2,785,000.00
Revenue This Year
$12.56
$49.08
Revenue Next Year
N/A
$26.69
P/E Ratio
$34.53
$446.04
Revenue Growth
N/A
N/A
52 Week Low
$84.25
$25.37
52 Week High
$151.95
$57.38

Technical Indicators

Market Signals
Indicator
CHRD
TGTX
Relative Strength Index (RSI) 30.91 64.31
Support Level $86.73 $28.57
Resistance Level $150.29 $57.38
Average True Range (ATR) 3.62 2.34
MACD -1.27 -0.14
Stochastic Oscillator 10.52 48.00

Price Performance

Historical Comparison
CHRD
TGTX

About CHRD Chord Energy Corporation

Chord Energy Corp is an independent exploration and production (E&P) company engaged in the acquisition, exploration, development and production of crude oil, NGL and natural gas prominently in the Williston Basin, with limited non-operated interests in the Marcellus Shale. It operates in one reportable business segment, which is the E&P of crude oil, NGL and natural gas. The company derives revenue from the sale of crude oil, NGL and natural gas production.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: